CLLS (cellectis.com) Long-Term Debt

The market trend for Cellectis S.A. (CLLS) on the GURU.Markets platform, as illustrated on this price chart, demonstrates long-term debt amounting to 0.08. Current price action is driven by a liquidity shortage and the costly process of developing new drugs. While the high cost of innovation and the risk of failed trials threaten stability, Cellectis S.A. (CLLS) generates revenue by selling the rights to use its gene modifications to major medical centers.

The specifics of Cellectis S.A. (CLLS) clinical trial outsourcing are reflected in the dynamics of the corporation's long-term loans and borrowings. This indicator aggregates all long-term liabilities, assessing the company's ability to attract low-cost capital to fund innovation. The metric measures the volume of borrowed funds with a maturity of over one year, determining the financial leverage for development. The balance between debt load and liquidity is critical for maintaining the pace of gene therapy.